Madhavi Patnana
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Madhavi Patnana has a total of 151 co-authors. Here are the top co-authors by number of shared publications:
- Priya Bhosale
The University of Texas MD Anderson Cancer Center, Houston, USA
7 shared publications - Brinda Rao Korivi
Abdominal Imaging Department, The University of Texas MD Anderson Cancer Center, Houston, USA
5 shared publications Brinda Rao Korivi
Department of Radiology, The University of Texas MD Anderson Cancer Center, Houston, USA
3 shared publications- Catherine E. Devine
Department of Abdominal Imaging, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
3 shared publications - Ott Le
The University of Texas MD Anderson Cancer Center
3 shared publications - Victor G. Prieto
Department of Pathology, Section of Dermatopathology The University of Texas MD Anderson Cancer Center Houston Texas USA
3 shared publications
Latest Publications
- 29 March 2025
- Published by Springer Nature in Dysphagia
- Vol. 40  (5) , 1240-1249
Fluoroscopy Time of Radiologist-Monitored Modified Barium Swallow Exams in Oncology: A 3-year Single Institution Retrospective Study
Fluoroscopy time is an important metric for radiation safety, but how it is related to dysphagia severity as graded by Dynamic Grade of Swallowing Toxicity (DIGEST) criteria and other factors in oncology practice is undocumented. We evaluated the fluoroscopy time for the bolus protocol used at the originating institution of the DIGEST method and assessed the relationship between fluoroscopy time and DIGEST grade, exam indication, and additional parameters. Eleven trials, including specified VARIBAR® barium volumes, were included in the standard bolus protocol. Electronic health record (EHR) 2018–2021 databases were sampled in a retrospective STARI-guided DIGEST implementation evaluation for clinically reported DIGEST grades in the EHR and matched to fluoroscopy time. The study sample included 4,162 modified barium swallow (MBS) examinations. Using generalized linear modeling, we tested log-transformed fluoroscopy time associations with Tukey’s adjustment for multiple pairwise comparisons. MBS duration ranged from 0.16 to 11.80 min (Median 2.21, IQR 1.98). Fluoroscopy time was associated with exam indication, cancer diagnosis, setting, and DIGEST grade. Fluoroscopy times increased as the DIGEST severity grade worsened (R2 = 0.45, p < .0001). MBS indication was also associated with fluoroscopy time (R2 = 0.12, p < .0001), with the shortest times for baseline exams and the longest for excluding leaks (Median1.6 vs. 3.5 min). Median fluoroscopy time was shorter among endocrine and metastatic cancer patients and longer among head and neck cancer patients (2 vs. 3 min, R2 = 0.02, p < .0001). Inpatient examinations were longer than outpatient (Median 3.1 vs. 2.2 min, R2 = 0.02, p < .0001). The bolus protocol was clinically acceptable within ALARA standards. Clinicians should be mindful of increased fluoroscopy time and optimize exams as clinically indicated in patients with severe dysphagia, leak exclusion, and inpatient studies.
- 29 March 2025
- Published by Springer Nature in Dysphagia
- Vol. 40  (5) , 1240-1249
Fluoroscopy Time of Radiologist-Monitored Modified Barium Swallow Exams in Oncology: A 3-year Single Institution Retrospective Study
Fluoroscopy time is an important metric for radiation safety, but how it is related to dysphagia severity as graded by Dynamic Grade of Swallowing Toxicity (DIGEST) criteria and other factors in oncology practice is undocumented. We evaluated the fluoroscopy time for the bolus protocol used at the originating institution of the DIGEST method and assessed the relationship between fluoroscopy time and DIGEST grade, exam indication, and additional parameters. Eleven trials, including specified VARIBAR® barium volumes, were included in the standard bolus protocol. Electronic health record (EHR) 2018–2021 databases were sampled in a retrospective STARI-guided DIGEST implementation evaluation for clinically reported DIGEST grades in the EHR and matched to fluoroscopy time. The study sample included 4,162 modified barium swallow (MBS) examinations. Using generalized linear modeling, we tested log-transformed fluoroscopy time associations with Tukey’s adjustment for multiple pairwise comparisons. MBS duration ranged from 0.16 to 11.80 min (Median 2.21, IQR 1.98). Fluoroscopy time was associated with exam indication, cancer diagnosis, setting, and DIGEST grade. Fluoroscopy times increased as the DIGEST severity grade worsened (R2 = 0.45, p < .0001). MBS indication was also associated with fluoroscopy time (R2 = 0.12, p < .0001), with the shortest times for baseline exams and the longest for excluding leaks (Median1.6 vs. 3.5 min). Median fluoroscopy time was shorter among endocrine and metastatic cancer patients and longer among head and neck cancer patients (2 vs. 3 min, R2 = 0.02, p < .0001). Inpatient examinations were longer than outpatient (Median 3.1 vs. 2.2 min, R2 = 0.02, p < .0001). The bolus protocol was clinically acceptable within ALARA standards. Clinicians should be mindful of increased fluoroscopy time and optimize exams as clinically indicated in patients with severe dysphagia, leak exclusion, and inpatient studies.
- 25 June 2024
- Published by Springer Nature in Abdominal Radiology
- Vol. 50  (1) , 467-479
GI and GU fluoroscopy in common post-op oncologic surgeries: what you need to know about this leaky business!
Over the past several years, there has been a trend of decreasing screening or diagnostic fluoroscopic examinations ordered by clinical teams, particularly double contrast gastrointestinal studies. The underlying reason is due to increasing number of endoscopic procedures performed by Gastroenterology and Urology and usage of other imaging modalities, which are either more sensitive and/or offer the ability to obtain tissue for confirmation. Many fluoroscopic studies are now tailored toward patients who have undergone gastrointestinal or genitourinary oncologic surgeries, providing both functional and anatomic information, which are important tools for patient management. Some of these surgeries are very complex and an understanding of the postoperative anatomy and potential pitfalls is important to accurately evaluate for complications. The purpose of this article is to describe techniques and indications for common post-operative fluoroscopic procedures in gastrointestinal and genitourinary oncology while reviewing normal appearances. Complications, with emphasis on postoperative leaks, will be highlighted. Familiarity with the various types of gastrointestinal surgeries and urinary diversion techniques and knowledge of the expected postsurgical appearance is essential for achieving an accurate and prompt diagnosis of complications to allow for adequate treatment and management. Graphical abstract
- 25 June 2024
- Published by Springer Nature in Abdominal Radiology
- Vol. 50  (1) , 467-479
GI and GU fluoroscopy in common post-op oncologic surgeries: what you need to know about this leaky business!
Over the past several years, there has been a trend of decreasing screening or diagnostic fluoroscopic examinations ordered by clinical teams, particularly double contrast gastrointestinal studies. The underlying reason is due to increasing number of endoscopic procedures performed by Gastroenterology and Urology and usage of other imaging modalities, which are either more sensitive and/or offer the ability to obtain tissue for confirmation. Many fluoroscopic studies are now tailored toward patients who have undergone gastrointestinal or genitourinary oncologic surgeries, providing both functional and anatomic information, which are important tools for patient management. Some of these surgeries are very complex and an understanding of the postoperative anatomy and potential pitfalls is important to accurately evaluate for complications. The purpose of this article is to describe techniques and indications for common post-operative fluoroscopic procedures in gastrointestinal and genitourinary oncology while reviewing normal appearances. Complications, with emphasis on postoperative leaks, will be highlighted. Familiarity with the various types of gastrointestinal surgeries and urinary diversion techniques and knowledge of the expected postsurgical appearance is essential for achieving an accurate and prompt diagnosis of complications to allow for adequate treatment and management. Graphical abstract
- Open Access
Gender Differences in a Mouse Model of Hepatocellular Carcinoma Revealed Using Multi-Modal Imaging
The worldwide incidence of hepatocellular carcinoma (HCC) continues to rise, in part due to poor diet, limited exercise, and alcohol abuse. Numerous studies have suggested that the loss or mutation of PTEN plays a critical role in HCC tumorigenesis through the activation of the PI3K/Akt signaling axis. The homozygous knockout of PTEN in the livers of mice results in the accumulation of fat (steatosis), inflammation, fibrosis, and eventually progression to HCC. This phenotype bears a striking similarity to non-alcoholic steatohepatitis (NASH) which is thought to occupy an intermediate stage between non-alcoholic fatty liver disease (NAFLD), fibrosis, and HCC. The molecular and physiological phenotypes that manifest during the transition to HCC suggest that molecular imaging could provide a non-invasive screening platform to identify the hallmarks of HCC initiation prior to the presentation of clinical disease. We have carried out longitudinal imaging studies on the liver-specific PTEN knockout mouse model using CT, MRI, and multi-tracer PET to interrogate liver size, steatosis, inflammation, and apoptosis. In male PTEN knockout mice, significant steatosis was observed as early as 3 months using both magnetic resonance spectroscopy (MRS) and computed tomography (CT). Enhanced uptake of the apoptosis tracer 18F-TBD was also observed in the livers of male PTEN homozygous knockout mice between 3 and 4 months of age relative to heterozygous knockout controls. Liver uptake of the inflammation tracer [18F]4FN remained relatively low and constant over 7 months in male PTEN homozygous knockout mice, suggesting the suppression of high-energy ROS/RNS with PTEN deletion relative to heterozygous males where the [18F]4FN liver uptake was elevated at early and late time points. All male PTEN homozygous mice developed HCC lesions by month 10. In contrast to the male cohort, only 20% (2 out of 10) of female PTEN homozygous knockout mice developed HCC lesions by month 10. Steatosis was significantly less pronounced in the female PTEN homozygous knockout mice relative to males and could not accurately predict the eventual occurrence of HCC. As with the males, the [18F]4FN uptake in female PTEN homozygous knockout mice was low and constant throughout the time course. The liver uptake of 18F-TBD at 3 and 4.5 months was higher in the two female PTEN knockout mice that would eventually develop HCC and was the most predictive imaging biomarker for HCC in the female cohort. These studies demonstrate the diagnostic and prognostic role of multi-modal imaging in HCC mouse models and provide compelling evidence that disease progression in the PTEN knockout model is highly dependent on gender.
Open AccessGender Differences in a Mouse Model of Hepatocellular Carcinoma Revealed Using Multi-Modal Imaging
The worldwide incidence of hepatocellular carcinoma (HCC) continues to rise, in part due to poor diet, limited exercise, and alcohol abuse. Numerous studies have suggested that the loss or mutation of PTEN plays a critical role in HCC tumorigenesis through the activation of the PI3K/Akt signaling axis. The homozygous knockout of PTEN in the livers of mice results in the accumulation of fat (steatosis), inflammation, fibrosis, and eventually progression to HCC. This phenotype bears a striking similarity to non-alcoholic steatohepatitis (NASH) which is thought to occupy an intermediate stage between non-alcoholic fatty liver disease (NAFLD), fibrosis, and HCC. The molecular and physiological phenotypes that manifest during the transition to HCC suggest that molecular imaging could provide a non-invasive screening platform to identify the hallmarks of HCC initiation prior to the presentation of clinical disease. We have carried out longitudinal imaging studies on the liver-specific PTEN knockout mouse model using CT, MRI, and multi-tracer PET to interrogate liver size, steatosis, inflammation, and apoptosis. In male PTEN knockout mice, significant steatosis was observed as early as 3 months using both magnetic resonance spectroscopy (MRS) and computed tomography (CT). Enhanced uptake of the apoptosis tracer 18F-TBD was also observed in the livers of male PTEN homozygous knockout mice between 3 and 4 months of age relative to heterozygous knockout controls. Liver uptake of the inflammation tracer [18F]4FN remained relatively low and constant over 7 months in male PTEN homozygous knockout mice, suggesting the suppression of high-energy ROS/RNS with PTEN deletion relative to heterozygous males where the [18F]4FN liver uptake was elevated at early and late time points. All male PTEN homozygous mice developed HCC lesions by month 10. In contrast to the male cohort, only 20% (2 out of 10) of female PTEN homozygous knockout mice developed HCC lesions by month 10. Steatosis was significantly less pronounced in the female PTEN homozygous knockout mice relative to males and could not accurately predict the eventual occurrence of HCC. As with the males, the [18F]4FN uptake in female PTEN homozygous knockout mice was low and constant throughout the time course. The liver uptake of 18F-TBD at 3 and 4.5 months was higher in the two female PTEN knockout mice that would eventually develop HCC and was the most predictive imaging biomarker for HCC in the female cohort. These studies demonstrate the diagnostic and prognostic role of multi-modal imaging in HCC mouse models and provide compelling evidence that disease progression in the PTEN knockout model is highly dependent on gender.
- Open Access
- 9 March 2023
- Published by Springer Nature in Nature
- Vol. 615  (7953) , E23
Author Correction: Neoadjuvant relatlimab and nivolumab in resectable melanoma
- 9 March 2023
- Published by Springer Nature in Nature
- Vol. 615  (7953) , E23
Open AccessAuthor Correction: Neoadjuvant relatlimab and nivolumab in resectable melanoma
- Top Cited PapersOpen Access
- 26 October 2022
- Published by Springer Nature in Nature
- Vol. 611  (7934) , 155-160
Neoadjuvant relatlimab and nivolumab in resectable melanoma
Relatlimab and nivolumab combination immunotherapy improves progression-free survival over nivolumab monotherapy in patients with unresectable advanced melanoma1. We investigated this regimen in patients with resectable clinical stage III or oligometastatic stage IV melanoma (NCT02519322). Patients received two neoadjuvant doses (nivolumab 480 mg and relatlimab 160 mg intravenously every 4 weeks) followed by surgery, and then ten doses of adjuvant combination therapy. The primary end point was pathologic complete response (pCR) rate2. The combination resulted in 57% pCR rate and 70% overall pathologic response rate among 30 patients treated. The radiographic response rate using Response Evaluation Criteria in Solid Tumors 1.1 was 57%. No grade 3–4 immune-related adverse events were observed in the neoadjuvant setting. The 1- and 2-year recurrence-free survival rate was 100% and 92% for patients with any pathologic response, compared to 88% and 55% for patients who did not have a pathologic response (P = 0.005). Increased immune cell infiltration at baseline, and decrease in M2 macrophages during treatment, were associated with pathologic response. Our results indicate that neoadjuvant relatlimab and nivolumab induces a high pCR rate. Safety during neoadjuvant therapy is favourable compared to other combination immunotherapy regimens. These data, in combination with the results of the RELATIVITY-047 trial1, provide further confirmation of the efficacy and safety of this new immunotherapy regimen.
- 26 October 2022
- Published by Springer Nature in Nature
- Vol. 611  (7934) , 155-160
Top Cited PapersOpen AccessNeoadjuvant relatlimab and nivolumab in resectable melanoma
Relatlimab and nivolumab combination immunotherapy improves progression-free survival over nivolumab monotherapy in patients with unresectable advanced melanoma1. We investigated this regimen in patients with resectable clinical stage III or oligometastatic stage IV melanoma (NCT02519322). Patients received two neoadjuvant doses (nivolumab 480 mg and relatlimab 160 mg intravenously every 4 weeks) followed by surgery, and then ten doses of adjuvant combination therapy. The primary end point was pathologic complete response (pCR) rate2. The combination resulted in 57% pCR rate and 70% overall pathologic response rate among 30 patients treated. The radiographic response rate using Response Evaluation Criteria in Solid Tumors 1.1 was 57%. No grade 3–4 immune-related adverse events were observed in the neoadjuvant setting. The 1- and 2-year recurrence-free survival rate was 100% and 92% for patients with any pathologic response, compared to 88% and 55% for patients who did not have a pathologic response (P = 0.005). Increased immune cell infiltration at baseline, and decrease in M2 macrophages during treatment, were associated with pathologic response. Our results indicate that neoadjuvant relatlimab and nivolumab induces a high pCR rate. Safety during neoadjuvant therapy is favourable compared to other combination immunotherapy regimens. These data, in combination with the results of the RELATIVITY-047 trial1, provide further confirmation of the efficacy and safety of this new immunotherapy regimen.
- Open Access
Preoperatively Treated Diffuse-Type Gastric Adenocarcinoma: Glucose vs. Other Energy Sources Substantially Influence Prognosis and Therapy Response
Diffuse type of gastric adenocarcinoma (dGAC) generally confers a poor prognosis compared to intestinal type. Some dGACs are not avid on fluorine-18 fluoro-2-deoxy-D-glucose PET (FDG-PET) while others seem to consume glucose avidly. We analyzed the outcomes based on the avidity (high with standardized uptake value (SUV) > 3.5 or low with SUV ≤ 3.5) of the primary on baseline FDG-PET. We retrospectively selected 111 localized dGAC patients who had baseline FDG-PET (all were treated with preoperative chemotherapy and chemoradiation). FDG-PET avidity was compared with overall survival (OS) and response to therapy. The mean age was 59.4 years and with many females (47.7%). The high-SUV group (58 (52.3%) patients) and the low-SUV group (53 (47.7%) patients) were equally divided. While the median OS for all patients was 49.5 months (95% CI: 38.5–98.8 months), it was 98.0 months (95% CI: 49.5–NE months) for the low-SUV group and 36.0 months for the high-SUV (p = 0.003). While the median DFS for all patients was 38.2 months (95% CI: 27.7–97.6 months), it was 98.0 (95% CI: 36.9–NE months) months for the low-SUV group was and only 27.0 months (95% CI: 15.2–63.2 months) for the high-SUV group (p = 0.005). Clinical responses before surgery were more common in the low-SUV group but overall we observed only 4 pathologic complete responses in 111 patients. Our unique data suggest that if dGACs used glucose as an energy source then the prognosis was very poor while non-glucose sources improved prognosis. Multi-platform (including metabolomics) profiling of dGACs would yield useful biologic understanding.
Open AccessPreoperatively Treated Diffuse-Type Gastric Adenocarcinoma: Glucose vs. Other Energy Sources Substantially Influence Prognosis and Therapy Response
Diffuse type of gastric adenocarcinoma (dGAC) generally confers a poor prognosis compared to intestinal type. Some dGACs are not avid on fluorine-18 fluoro-2-deoxy-D-glucose PET (FDG-PET) while others seem to consume glucose avidly. We analyzed the outcomes based on the avidity (high with standardized uptake value (SUV) > 3.5 or low with SUV ≤ 3.5) of the primary on baseline FDG-PET. We retrospectively selected 111 localized dGAC patients who had baseline FDG-PET (all were treated with preoperative chemotherapy and chemoradiation). FDG-PET avidity was compared with overall survival (OS) and response to therapy. The mean age was 59.4 years and with many females (47.7%). The high-SUV group (58 (52.3%) patients) and the low-SUV group (53 (47.7%) patients) were equally divided. While the median OS for all patients was 49.5 months (95% CI: 38.5–98.8 months), it was 98.0 months (95% CI: 49.5–NE months) for the low-SUV group and 36.0 months for the high-SUV (p = 0.003). While the median DFS for all patients was 38.2 months (95% CI: 27.7–97.6 months), it was 98.0 (95% CI: 36.9–NE months) months for the low-SUV group was and only 27.0 months (95% CI: 15.2–63.2 months) for the high-SUV group (p = 0.005). Clinical responses before surgery were more common in the low-SUV group but overall we observed only 4 pathologic complete responses in 111 patients. Our unique data suggest that if dGACs used glucose as an energy source then the prognosis was very poor while non-glucose sources improved prognosis. Multi-platform (including metabolomics) profiling of dGACs would yield useful biologic understanding.
- 1 July 2019
- Published by Elsevier in Clinical Imaging
- Vol. 56, 33-40
Intestinal and diffuse gastric cancer: a retrospective study comparing primary sites
- 1 July 2019
- Published by Elsevier in Clinical Imaging
- Vol. 56, 33-40
Intestinal and diffuse gastric cancer: a retrospective study comparing primary sites
- 1 September 2018
- Published by Elsevier in Current Problems in Diagnostic Radiology
- Vol. 47  (5) , 333-339
Small Cell Carcinoma of the Ovary, Hypercalcemic Type: Clinical and Imaging Review
- 1 September 2018
- Published by Elsevier in Current Problems in Diagnostic Radiology
- Vol. 47  (5) , 333-339
Small Cell Carcinoma of the Ovary, Hypercalcemic Type: Clinical and Imaging Review
- Open Access
- 1 July 2018
- Published by Wolters Kluwer Health in Journal of Immunotherapy
- Vol. 41  (6) , 284-291
Evaluating for Pseudoprogression in Colorectal and Pancreatic Tumors Treated With Immunotherapy
Pseudoprogression has been observed in patients with various tumor types treated with immunotherapy. However, the frequency of pseudoprogression is unknown in gastrointestinal malignancies. Metastatic colorectal cancer (mCRC) and advanced pancreatic ductal adenocarcinoma (PDAC) patients who progressed on treatment with immunotherapy beyond RECIST version 1.1 criteria were analyzed. Degree of progression, tumor markers, time to progression, overall survival, Eastern Cooperative Oncology Group Performance Status (ECOG PS), and costs were analyzed for patients treated beyond progression (TBP) and not treated beyond progression. Fifty-nine of 159 (37%) patients with mCRC or PDAC were TBP (31 mCRC, 28 PDAC). Fifty-four of 59 (92%) patients were microsatellite stable. Zero of these 59 patients with initial treatment beyond progression demonstrated subsequent radiographic tumor shrinkage at a median 42 days from first scan documenting progression. A pseudoprogression rate of >6% could be excluded with 95% confidence. Compared with baseline, median growth on the first and second scan that showed progression was 29.8% and 43%, respectively. In those not treated beyond progression, median growth at first restaging was 31.2%. The trend in change in tumor size positively correlated with the trend in tumor markers in all patients TBP. Fifteen patients (25%) experienced grade 3/4 adverse events by continuing treatment beyond progression, whereas 19 (32%) experienced deterioration in ECOG PS. Pseudoprogression was not seen in microsatellite stable patients with mCRC or PDAC treated with immunotherapy. Changes in tumor markers correlated with changes in tumor volume. This data may help inform future treatment decisions and/or trial design in patients with mCRC or advanced PDAC treated with immunotherapy.
- 1 July 2018
- Published by Wolters Kluwer Health in Journal of Immunotherapy
- Vol. 41  (6) , 284-291
Open AccessEvaluating for Pseudoprogression in Colorectal and Pancreatic Tumors Treated With Immunotherapy
Pseudoprogression has been observed in patients with various tumor types treated with immunotherapy. However, the frequency of pseudoprogression is unknown in gastrointestinal malignancies. Metastatic colorectal cancer (mCRC) and advanced pancreatic ductal adenocarcinoma (PDAC) patients who progressed on treatment with immunotherapy beyond RECIST version 1.1 criteria were analyzed. Degree of progression, tumor markers, time to progression, overall survival, Eastern Cooperative Oncology Group Performance Status (ECOG PS), and costs were analyzed for patients treated beyond progression (TBP) and not treated beyond progression. Fifty-nine of 159 (37%) patients with mCRC or PDAC were TBP (31 mCRC, 28 PDAC). Fifty-four of 59 (92%) patients were microsatellite stable. Zero of these 59 patients with initial treatment beyond progression demonstrated subsequent radiographic tumor shrinkage at a median 42 days from first scan documenting progression. A pseudoprogression rate of >6% could be excluded with 95% confidence. Compared with baseline, median growth on the first and second scan that showed progression was 29.8% and 43%, respectively. In those not treated beyond progression, median growth at first restaging was 31.2%. The trend in change in tumor size positively correlated with the trend in tumor markers in all patients TBP. Fifteen patients (25%) experienced grade 3/4 adverse events by continuing treatment beyond progression, whereas 19 (32%) experienced deterioration in ECOG PS. Pseudoprogression was not seen in microsatellite stable patients with mCRC or PDAC treated with immunotherapy. Changes in tumor markers correlated with changes in tumor volume. This data may help inform future treatment decisions and/or trial design in patients with mCRC or advanced PDAC treated with immunotherapy.
- 1 July 2018
- Published by American Roentgen Ray Society in American Journal of Roentgenology
- Vol. 211  (1) , 76-86
Liver Calcifications and Calcified Liver Masses: Pattern Recognition Approach on CT
OBJECTIVE. Because of the ubiquitous use of radiologic imaging, particularly with CT, the detection of focal hepatic calcifications has increased. Calcifications can be seen in cystic and solid masses associated with both benign and malignant causes, pseudomasses, and miscellaneous pathologic abnormalities. CONCLUSION. These calcifications can manifest in various patterns, recognition of which can increase specificity for various diagnoses. In this article, we review a wide range of calcified hepatic pathologic abnormalities at CT and propose an approach for diagnosis.
- 1 July 2018
- Published by American Roentgen Ray Society in American Journal of Roentgenology
- Vol. 211  (1) , 76-86
Liver Calcifications and Calcified Liver Masses: Pattern Recognition Approach on CT
OBJECTIVE. Because of the ubiquitous use of radiologic imaging, particularly with CT, the detection of focal hepatic calcifications has increased. Calcifications can be seen in cystic and solid masses associated with both benign and malignant causes, pseudomasses, and miscellaneous pathologic abnormalities. CONCLUSION. These calcifications can manifest in various patterns, recognition of which can increase specificity for various diagnoses. In this article, we review a wide range of calcified hepatic pathologic abnormalities at CT and propose an approach for diagnosis.